Vitex and calcium have trials. PMDD is a different, more serious diagnosis and needs clinical care.
Premenstrual syndrome is a cluster of physical and emotional symptoms in the luteal phase that resolves with menstruation. Premenstrual dysphoric disorder (PMDD) is a more severe, recognised condition with significant mood symptoms and functional impairment, and it is a different diagnosis with different treatment.
The diagnostic point that matters. The symptoms must be cyclical and confined to the luteal phase, and the way to establish that is a prospective daily symptom diary over 2-3 cycles, not recollection. Many things that get called PMS — depression, thyroid disease, anaemia, perimenopause — are not cyclical, and the diary is what separates them. This is the most useful single action on the page.
Vitex agnus-castus (chasteberry) has several randomised trials showing improvement in premenstrual symptoms over placebo, and it is the best-studied herb for PMS. It works on dopaminergic pathways and can affect prolactin. Cautions: it can interfere with hormonal contraception's effectiveness in some reports by altering prolactin, it should not be used in pregnancy, and it should not be combined with dopamine-related drugs.
Calcium at 1000-1200 mg daily has randomised evidence for premenstrual symptoms, which is an unusually well-supported nutrient intervention.
Evening primrose oil has been used for decades and the trials are largely negative.
For PMDD specifically, the treatments with evidence are SSRIs (which can be taken continuously or only in the luteal phase, and which work faster in PMDD than in depression), a specific combined oral contraceptive, and GnRH analogues in severe cases. A person with significant premenstrual mood symptoms, especially with hopelessness or suicidal thoughts, needs clinical care. This is not a supplement situation.
Other measures with evidence. Aerobic exercise, reducing caffeine and alcohol, adequate sleep, and cognitive behavioural approaches.
Meta-Analysis2025Nutrition reviews
Effect of Saffron Versus Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment of Depression and Anxiety: A Meta-analysis of Randomized Controlled Trials.
Saffron could be a potential SSRI alternative to reduce depressive and anxiety symptoms with fewer adverse events.
PubMed 38913392 ↗
Meta-Analysis2025Psychological medicine
Comparative efficacy and tolerability of nutraceuticals for depressive disorder: A systematic review and network meta-analysis.
This extensive systematic review and NMA of nutraceuticals for treating depressive disorders indicated a number of nutraceuticals that could offer benefits, either as adjuncts or monotherapies.
PubMed 40314175 ↗
Meta-Analysis2024The Cochrane database of systematic reviews
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder.
SSRIs probably reduce premenstrual symptoms in women with PMS and PMDD and are probably more effective when taken continuously compared to luteal phase administration.
PubMed 39140320 ↗
Meta-Analysis2024Phytotherapy research : PTR
New horizons for the study of saffron (Crocus sativus L.) and its active ingredients in the management of neurological and psychiatric disorders: A systematic review of clinical evidence and mechanisms.
Saffron may exert protective roles for neurological and psychiatric disorders and represents a relatively favorable and safe treatment.
PubMed 38424688 ↗
Meta-Analysis2023Frontiers in neuroendocrinology
A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy.
Research in PMD, MM, and CE commonly have overlapping study design and research methods, and similar effects of some interventions suggest the possibility of overlapping mechanisms contributing to their cyclical symptom presentation.
PubMed 37619655 ↗